The Combination of Gefitinib With ATRA and ATO Induces Myeloid Differentiation in Acute Promyelocytic Leukemia Resistant Cells

The Combination of Gefitinib With ATRA and ATO Induces Myeloid Differentiation in Acute Promyelocytic Leukemia Resistant Cells

In approximately 15% of patients with acute myeloid leukemia (AML), total and phosphorylated EGFR proteins have been reported to be increased compared to healthy CD34+ samples. However, it is unclear if this subset of patients would benefit from EGFR signaling pharmacological inhibition. Pre-clinica...

Full description

Bibliographic Details
Main Authors: Luciana Yamamoto de Almeida, Diego A. Pereira-Martins, Isabel Weinhäuser, César Ortiz, Larissa A. Cândido, Ana Paula Lange, Nayara F. De Abreu, Sílvia E. S. Mendonza, Virgínia M. de Deus Wagatsuma, Mariane C. Do Nascimento, Helder H. Paiva, Raquel M. Alves-Paiva, Camila C. O. M. Bonaldo, Daniele C. Nascimento, José C. Alves-Filho, Priscila S. Scheucher, Ana Sílvia G. Lima, Jan Jacob Schuringa, Emanuele Ammantuna, Tiziana Ottone, Nelida I. Noguera, Cleide L. Araujo, Eduardo M. Rego
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
epidermal growth factor receptor (EGFR)
erlotinib
gefitinib
all-trans retinoic acid (ATRA)
acute promyelocytic leukemia (APL)
ATRA-resistance
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.686445/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.686445/full

Similar Items